Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium.
Brickley, Elizabeth B;
Connor, Ruth I;
Wieland-Alter, Wendy;
Weiner, Joshua A;
Ackerman, Margaret E;
Arita, Minetaro;
Gast, Chris;
De Coster, Ilse;
Van Damme, Pierre;
Bandyopadhyay, Ananda S;
+1 more...Wright, Peter F;
(2020)
Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium.
The Journal of infectious diseases, 226 (2).
pp. 287-291.
ISSN 0022-1899
DOI: https://doi.org/10.1093/infdis/jiaa783
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
In a blinded phase 1 trial (EudraCT 2017-0000908-21; NCT03430349) in Belgium, healthy adults (aged 18-50 years) previously immunized exclusively with inactivated poliovirus vaccine were administered a single dose of 1 of 2 novel type 2 oral poliovirus vaccines (nOPV2-c1: S2/cre5/S15domV/rec1/hifi3 (n = 15); nOPV2-c2: S2/S15domV/CpG40 (n = 15)) and isolated for 28 days in a purpose-built containment facility. Using stool samples collected near days 0, 14, 21, and 28, we evaluated intestinal neutralization and immunoglobulin A responses to the nOPV2s and found that nOPV2-c1 and nOPV2-c2 induced detectable poliovirus type 2-specific intestinal neutralizing responses in 40.0% and 46.7% of participants, respectively.